S.J.H. van Deventer
S.J.H. van Deventer
Leiden University Medical Center
Verified email at xs4all.nl - Homepage
Title
Cited by
Cited by
Year
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
SR Targan, SB Hanauer, SJH Van Deventer, L Mayer, DH Present, ...
New England Journal of Medicine 337 (15), 1029-1036, 1997
36981997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
SR Targan, SB Hanauer, SJH Van Deventer, L Mayer, DH Present, ...
New England Journal of Medicine 337 (15), 1029-1036, 1997
36661997
Infliximab for the treatment of fistulas in patients with Crohn's disease
DH Present, P Rutgeerts, S Targan, SB Hanauer, L Mayer, ...
New England Journal of Medicine 340 (18), 1398-1405, 1999
30041999
Infliximab for the treatment of fistulas in patients with Crohn's disease
DH Present, P Rutgeerts, S Targan, SB Hanauer, L Mayer, ...
New England Journal of Medicine 340 (18), 1398-1405, 1999
30041999
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, ...
New England Journal of Medicine 350 (9), 876-885, 2004
22682004
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
HM Van Dullemen, SJH van Deventer, DW Hommes, HA Bijl, J Jansen, ...
Gastroenterology 109 (1), 129-135, 1995
12991995
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations
J Hampe, A Cuthbert, PJP Croucher, MM Mirza, S Mascheretti, S Fisher, ...
The Lancet 357 (9272), 1925-1928, 2001
12892001
Polyp miss rate determined by tandem colonoscopy: a systematic review
JC Van Rijn, JB Reitsma, J Stoker, PM Bossuyt, SJ Van Deventer, ...
American Journal of Gastroenterology 101 (2), 343-350, 2006
12302006
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
P Rutgeerts, G D'Haens, S Targan, E Vasiliauskas, SB Hanauer, ...
Gastroenterology 117 (4), 761-769, 1999
12301999
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
G D'Haens, F Baert, G Van Assche, P Caenepeel, P Vergauwe, ...
The Lancet 371 (9613), 660-667, 2008
11962008
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
SJ Van Deventer, HR Buller, JW Ten Cate, LA Aarden, CE Hack, A Sturk
10411990
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn, JF Colombel, R Enns, BG Feagan, SB Hanauer, ...
New England Journal of Medicine 353 (18), 1912-1925, 2005
9122005
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
G D'Haens, S Van Deventer, R Van Hogezand, D Chalmers, C Kothe, ...
Gastroenterology 116 (5), 1029-1034, 1999
8301999
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease
JMH Van den Brande, H Braat, GR van den Brink, HH Versteeg, ...
Gastroenterology 124 (7), 1774-1785, 2003
8242003
Activation of coagulation after administration of tumor necrosis factor to normal subjects
T van der Poll, HR Büller, H ten Cate, CH Wortel, KA Bauer, ...
New England Journal of Medicine 322 (23), 1622-1627, 1990
7691990
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease
H Braat, P Rottiers, DW Hommes, N Huyghebaert, E Remaut, JP Remon, ...
Clinical gastroenterology and hepatology 4 (6), 754-759, 2006
7032006
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
T Ten Hove, C Van Montfrans, MP Peppelenbosch, SJH Van Deventer
Gut 50 (2), 206-211, 2002
6502002
Mucosal tumor necrosis factor-or, interleukin-1/3, and interleukin-8 production in patients with helicobacter pylori infection
LA Noach, NB Bosma, J Jansen, FJ Hoek, SJH Van Deventer, GNJ Tytgat
Scandinavian journal of gastroenterology 29 (5), 425-429, 1994
6191994
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
RN Fedorak, A Gangl, CO Elson, P Rutgeerts, S Schreiber, G Wild, ...
Gastroenterology 119 (6), 1473-1482, 2000
5802000
Tumour necrosis factor and Crohn's disease.
SJ Van Deventer
Gut 40 (4), 443, 1997
5791997
The system can't perform the operation now. Try again later.
Articles 1–20